Diana Boraschi

Q: What Schools Are Affiliated With Diana Boraschi

Diana Boraschi is affiliated with the following schools: University of California, Berkeley, Stanford University, University of Siena, University of Turin, Sapienza University of Rome

Diana Boraschi's AcademicInfluence.com Rankings

Diana Boraschi

Engineering

#6219

World Rank

#7533

Historical Rank

Biomedical Engineering

#533

World Rank

#543

Historical Rank

engineering Degrees

Download Badge

Engineering

Diana Boraschi's Degrees

PhD Biomedical Engineering University of California, Berkeley
Masters Biomedical Engineering University of California, Berkeley
Bachelors Biomedical Engineering University of California, Berkeley

Why Is Diana Boraschi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Diana Boraschi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation (2014) (1381)
Regulation of the macrophage content of neoplasms by chemoattractants. (1983) (365)
IL-37: a new anti-inflammatory cytokine of the IL-1 family. (2011) (316)
IL-1 family nomenclature (2010) (302)
IL-18 in autoimmunity: review. (2006) (226)
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. (2017) (210)
Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. (1990) (207)
Nanoparticles and innate immunity: new perspectives on host defence. (2017) (199)
The family of the interleukin‐1 receptors (2018) (189)
Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1. (1992) (180)
Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects (2011) (176)
The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. (1998) (167)
Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. (2004) (164)
Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. (1984) (146)
The interleukin-1 receptor family. (2013) (145)
Endotoxin contamination: a key element in the interpretation of nanosafety studies. (2016) (140)
A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. (1986) (135)
Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. (2010) (134)
Concern-driven integrated approaches to nanomaterial testing and assessment – report of the NanoSafety Cluster Working Group 10 (2013) (134)
IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease (2003) (128)
Engineered nanoparticles. How brain friendly is this new guest? (2014) (124)
Morphological characterization of a cell population responsible for natural killer activity. (1981) (122)
The Gracefully Aging Immune System (2013) (119)
Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. (2005) (117)
Role of Metalloproteases in the Release of the IL-1 type II Decoy Receptor* (1997) (115)
Antibody-dependent cell-mediated antibacterial activity of intestinal lymphocytes with secretory IgA (1983) (109)
Natural and antibody-dependent cell-mediated activity against Salmonella typhimurium by peripheral and intestinal lymphoid cells in mice. (1983) (109)
Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? (2012) (101)
Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. (2012) (101)
Innate Immune Memory in Invertebrate Metazoans: A Critical Appraisal (2018) (100)
Immunomodulatory activity of andrographolide on macrophage activation and specific antibody response (2010) (99)
The suitability of different cellular in vitro immunotoxicity and genotoxicity methods for the analysis of nanoparticle-induced events (2010) (93)
In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta. (1987) (92)
Cytokine Production (IL-1α, IL-1β, and TNFα) and Endothelial Cell Activation (ELAM-1 and HLA-DR) in Reactive Lymphadenitis, Hodgkin's Disease, and in Non-Hodgkin's Lymphomas: An Immunocytochemical Study (1990) (88)
Transcriptomic Profiling of the Development of the Inflammatory Response in Human Monocytes In Vitro (2014) (84)
In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta (1988) (82)
The Membrane Form of the Type II IL-1 Receptor Accounts for Inhibitory Function1 (2000) (80)
Natural killer activity of gut mucosal lymphoid cells in mice (1981) (80)
Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression? (2018) (77)
Model of interaction of the IL‐1 receptor accessory protein IL‐1RAcP with the IL‐1β/IL‐1RI complex (2001) (76)
IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. (1986) (71)
Regulation of arachidonic acid metabolism in macrophages by immune and nonimmune interferons. (1985) (71)
IL‐18 Activity in Systemic Lupus Erythematosus (2009) (71)
Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. (2009) (71)
PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. (2010) (69)
Immunosenescence and vaccine failure in the elderly: strategies for improving response. (2014) (67)
Endotoxin Contamination in Nanomaterials Leads to the Misinterpretation of Immunosafety Results (2017) (67)
IgA-dependent cell-mediated activity against enteropathogenic bacteria: distribution, specificity, and characterization of the effector cells. (1984) (66)
Bacterial endotoxin (lipopolysaccharide) binds to the surface of gold nanoparticles, interferes with biocorona formation and induces human monocyte inflammatory activation (2017) (66)
Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis (2014) (63)
Innate Immune Memory: Time for Adopting a Correct Terminology (2018) (63)
Structure-function relationship in the IL-1 family. (1996) (62)
Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective (2017) (62)
Differential binding of IL‐ 1α and IL‐ 1β to receptors on B and T cells (1989) (60)
Enhancement of in vivo immune response by tumor necrosis factor. (1987) (60)
Cellular immunity against Salmonella typhi after live oral vaccine. (1985) (58)
Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. (2010) (57)
Macrophage activation for tumor cytotoxicity: genetic variation in macrophage tumoricidal capacity among mouse strains. (1979) (56)
Ageing and immunity: addressing immune senescence to ensure healthy ageing. (2010) (56)
In vitro generated mast cells express natural cytotoxicity against tumour cells. (1985) (56)
The IL-1 family cytokines and receptors in autoimmune diseases. (2020) (56)
New Insights Into Tissue Macrophages: From Their Origin to the Development of Memory (2015) (53)
Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: Evidence for a role in the regulation of the macrophage content of neoplastic tissues (1983) (52)
Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice. (1979) (52)
Differential activity of interleukin 1α and interleukin 1β in the stimulation of the immune response in vivo (1990) (51)
Immunity against HIV/AIDS, Malaria, and Tuberculosis during Co-Infections with Neglected Infectious Diseases: Recommendations for the European Union Research Priorities (2008) (48)
Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells. (1997) (48)
From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology (2015) (48)
Interferon inhibits prostaglandin biosynthesis in macrophages: effects on arachidonic acid metabolism. (1984) (47)
Optimising the use of commercial LAL assays for the analysis of endotoxin contamination in metal colloids and metal oxide nanoparticles (2015) (47)
The bio-nano-interface in predicting nanoparticle fate and behaviour in living organisms: towards grouping and categorising nanomaterials and ensuring nanosafety by design (2013) (46)
Natural anti-bacterial activity against Salmonella typhi by human T4+ lymphocytes armed with IgA antibodies. (1985) (46)
Interferon‐induced enhancement of macrophage‐mediated tumor cytolysis and its difference from activation by lymphokines (1981) (46)
Different Regulation of Interleukin-1 Production and Activity in Monocytes and Macrophages: Innate Memory as an Endogenous Mechanism of IL-1 Inhibition (2017) (46)
Innate Immune Memory: The Latest Frontier of Adjuvanticity (2015) (44)
Immunohistochemical localization of IL-1 alpha and IL-1 beta in normal human placenta. (1991) (44)
IL-1 family cytokines and soluble receptors in systemic lupus erythematosus (2018) (43)
Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. (2013) (43)
Interleukin‐1β induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti‐tumor effects of tumor necrosis factor α or β (1989) (43)
In vivo restoration of T cell functions by human IL-1 beta or its 163-171 nonapeptide in immunodepressed mice. (1988) (42)
Personalized risk prediction of postoperative cognitive impairment – rationale for the EU-funded BioCog project (2018) (42)
Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines (1988) (42)
Immunoreactivity for IL-1 beta and TNF alpha in human lymphoid and nonlymphoid tissues. (1989) (41)
Macrophage activation by interferon: dissociation between tumoricidal capacity and suppressive activity (1982) (41)
Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171. (1993) (41)
Specific immune response to HBsAg is enhanced by beta-glucan oligosaccharide containing an alpha-(1-->3)-linked bond and biased towards M2/Th2. (2007) (40)
Lymphocytes from Autoimmune MRL lpr/lpr Mice Are Hyperresponsive to IL-18 and Overexpress the IL-18 Receptor Accessory Chain1 (2001) (40)
Defective tumoricidal capacity of macrophages from A/J mice. I. Characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli. (1979) (38)
Assessing the Immunosafety of Engineered Nanoparticles with a Novel in Vitro Model Based on Human Primary Monocytes. (2016) (38)
Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? (2009) (36)
Defective tumoricidal capacity of macrophages from A/J mice. III. Genetic analysis of the macrophage defect. (1980) (36)
Bovine colon organoids: From 3D bioprinting to cryopreserved multi-well screening platforms. (2019) (36)
β-Glucan Oligosaccharide Enhances CD8+ T Cells Immune Response Induced by a DNA Vaccine Encoding Hepatitis B Virus Core Antigen (2010) (36)
In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii (2003) (35)
Glycosylation enhances functional stability of the chemotactic cytokine CCL2. (2003) (34)
A monoclonal antibody to the IL-1 beta peptide 163-171 blocks adjuvanticity but not pyrogenicity of IL-1 beta in vivo. (1989) (34)
Cytokine-associated tissue injury and lethality in mice: a comparative study. (1991) (33)
MafB is a downstream target of the IL-10/STAT3 signaling pathway, involved in the regulation of macrophage de-activation. (2014) (32)
The association between frailty and MRI features of cerebral small vessel disease (2019) (32)
Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses. (1981) (31)
Interleukin-1 beta primes interleukin-8-stimulated chemotaxis and elastase release in human neutrophils via its type I receptor. (1997) (30)
Endothelial cells express the interleukin-1 receptor type I (1991) (30)
Interleukin-1 and interleukin-1 fragments as vaccine adjuvants. (1999) (30)
IFN-beta-induced reduction of superoxide anion generation by macrophages. (1982) (30)
Comparison of human interleukin-1 beta and its 163-171 peptide in bone resorption and the immune response. (1991) (29)
IgA-driven antibacterial activity against Streptococcus pneumoniae by mouse lung lymphocytes. (1988) (29)
Development and Functional Differentiation of Tissue-Resident Versus Monocyte-Derived Macrophages in Inflammatory Reactions. (2017) (29)
Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4. (1995) (29)
Defective tumoricidal capacity of macrophages from P/J mice: tumoricidal defect involves abnormalities in lymphokine-derived activation stimuli and in mononuclear phagocyte responsiveness. (1980) (28)
Addressing Nanomaterial Immunosafety by Evaluating Innate Immunity across Living Species. (2020) (28)
Lymphokine-activated tumor inhibition in mice. Ability of a nonapeptide of the human IL-1 beta to recruit anti-tumor reactivity in recipient mice. (1989) (28)
Induction of Innate Immune Memory by Engineered Nanoparticles: A Hypothesis That May Become True (2017) (28)
Macrophage activation for tumor cytotoxicity: analysis of intermediary reactions. (1979) (27)
Interferon decreases production of hydrogen peroxide by macrophages: correlation with reduction of suppressive capacity and of anti-microbial activity. (1983) (27)
The interleukin-1 receptor family. (2006) (27)
Regulation of macrophage suppression and cytotoxicity by interferon role of Ia-bearing macrophages. (1982) (27)
Correlation between the lipopolysaccharide response of mice and the capacity of mouse peritoneal cells to transfer an antiviral state. Role of endogenous interferon. (1987) (27)
Type II interleukin-1 receptor is not expressed in cultured endothelial cells and is not involved in endothelial cell activation (1993) (25)
Single-cell analysis of macrophage chemotactic protein-1-regulated cytosolic Ca2+ increase in human adherent monocytes. (1995) (25)
Towards nanotechnology regulation — Publish the unpublishable (2011) (24)
Modulation of macrophage suppressive activity and prostaglandin release by lymphokines and interferon: comparison of alveolar, pleural and peritoneal macrophages. (1984) (24)
Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra-like domains. (1995) (23)
Nanoparticles and the immune system : safety and effects (2014) (23)
Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study. (1990) (22)
Gold Nanoparticles Modulate BCG-Induced Innate Immune Memory in Human Monocytes by Shifting the Memory Response towards Tolerance (2020) (22)
Interleukin 1 stimulates production of LTC4 and other eicosanoids by macrophages. (1989) (22)
Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. (1990) (21)
Interferons inhibit LTC4 production in murine macrophages. (1987) (20)
In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment (2019) (20)
Towards bio-compatible magnetic nanoparticles: Immune-related effects, in-vitro internalization, and in-vivo bio-distribution of zwitterionic ferrite nanoparticles with unexpected renal clearance. (2020) (20)
Mapping of biologically relevant sites on human IL-1 beta using monoclonal antibodies. (1988) (20)
Immunomodulatory Activity of a Novel, Synthetic Beta-glucan (β-glu6) in Murine Macrophages and Human Peripheral Blood Mononuclear Cells (2013) (20)
Binding and internalization of the 163-171 fragment of human IL-1 beta. (1992) (19)
Dissociation between macrophage tumoricidal capacity and suppressive activity: analysis with macrophage-defective mouse strains. (1983) (18)
Structure-function relationship of interleukin-1 giving new insights for its therapeutic potential (1989) (18)
Endothelial cells express the interleukin-1 receptor type I. (1991) (18)
Profiling the Course of Resolving vs. Persistent Inflammation in Human Monocytes: The Role of IL-1 Family Molecules (2020) (16)
PRO cytokine strategies (1991) (16)
The Impact of Nanoparticles on Innate Immune Activation by Live Bacteria (2020) (16)
Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II. (1997) (16)
A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination (2022) (16)
IL‐1 family cytokines and receptors in IgG4‐related disease (2017) (16)
Genetic control of in vitro natural cell-mediated activity against Salmonella typhimurium by intestinal and splenic lymphoid cells in mice. (1984) (15)
Induction of long-term immunity against respiratory syncytial virus glycoprotein by an osmotic polymeric nanocarrier. (2014) (15)
Functional epitope mapping of human interleukin-1 beta by surface plasmon resonance. (1997) (15)
Different conformation of purified human recombinant interleukin 1 beta from Escherichia coli and Saccharomyces cerevisiae is related to different level of biological activity. (1989) (15)
The Interactions between Nanoparticles and the Innate Immune System from a Nanotechnologist Perspective (2021) (15)
One-step immunoaffinity purification of bioactive human recombinant IL-1 beta with a monoclonal antibody directed to a well-exposed domain of the protein. (1989) (14)
Macrophage antitumor activity in vitro. Comparative analysis of cytolytic, cytostatic, and cytotoxic activities of mouse macrophages and human monocytes. (1984) (14)
Biological role of the IL-1 receptor type II (IL-1RII) as defined by a monoclonal antibody (1991) (14)
Balance between autocrine interleukin-1beta and caspases defines life versus death of polymorphonuclear cells. (2001) (14)
Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria (2004) (14)
Cytokines in inflammation (1998) (13)
Defining the structural requirements of a biologically active domain of human IL-1 beta. (1990) (13)
Differential activity of interleukin 1 alpha and interleukin 1 beta in the stimulation of the immune response in vivo. (1990) (13)
Induction of Innate Immune Memory by Engineered Nanoparticles in Monocytes/Macrophages: From Hypothesis to Reality (2020) (13)
Defective tumoricidal capacity of macrophages from P/J mice: characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli. (1979) (13)
Development of cell-mediated antiviral immunity and macrophage activation in C3H/HeN mice infected with mouse mammary tumor virus. (1980) (13)
Interaction of nanoparticles with endotoxin Importance in nanosafety testing and exploitation for endotoxin binding (2021) (12)
Modulation of in vitro natural cell-mediated activity against enteropathogenic bacteria by simple sugars (1985) (12)
Species‐restricted effects of human and mouse lymphokines on macrophages (1980) (12)
Mechanism of acute toxicity of IL-1 beta in mice. (1991) (12)
Lymphokine‐activated tumor inhibition: Combinatory activity of a synthetic nonapeptide from interleukin‐1, interleukin‐2, interleukin‐4, and interferon‐γ injected around tumor‐draining lymph nodes (1989) (11)
Murine interferon-gamma/interleukin-1 fusion proteins used as antigens for the generation of hybridomas producing monoclonal anti-interleukin-1 antibodies. (1991) (11)
Probing the immune responses to nanoparticles across environmental species. A perspective of the EU Horizon 2020 project PANDORA (2020) (11)
Defining agonist peptides of human interleukin-1 beta. (1989) (11)
Macrophages and interdigitating reticulum cells in normal human thymus and thymomas: immunoreactivity for interleukin‐1 alpha, interleukin‐1 beta and tumour necrosis factor alpha (1990) (11)
Effect of carrier priming on antibody avidity in the in vivo and in vitro immune response. (1977) (10)
Editorial: Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicine (2017) (10)
LARGE GRANULAR LYMPHOCYTES AS EFFECTOR CELLS OF NATURAL KILLER ACTIVITY IN THE MOUSE (1982) (10)
Interaction between Macrophages and Nanoparticles: In Vitro 3D Cultures for the Realistic Assessment of Inflammatory Activation and Modulation of Innate Memory (2021) (10)
Macrophage antitumor activity: impaired responsiveness to interferon‐γ of macrophages from genetically defective mice (1984) (9)
Binding of IL-1 beta to IL-1R type II at single cell level. (1991) (9)
Perspectives in immunopharmacology: the future of immunosuppression. (2014) (9)
Radiation protection and restoration by the synthetic 163-171 nonapeptide of human interleukin 1 beta. (1991) (9)
Differential binding of IL-1 alpha and IL-1 beta to receptors on B and T cells. (1989) (9)
IL-18 and IL-18 receptors in the development of autoimmunity. (2000) (9)
The immunostimulatory effect of IL‐1β in vivo is blocked by antisense peptides complementary to the loop sequence 163–171 (2009) (9)
Surface Exposure of PEG and Amines on Biodegradable Nanoparticles as a Strategy to Tune Their Interaction with Protein-Rich Biological Media (2019) (9)
Purification of human recombinant interleukin 1 receptor antagonist proteins upon Bacillus subtilis sporulation. (1997) (8)
Cytokines and soluble receptors of the interleukin-1 family in Schnitzler syndrome (2019) (8)
Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma (2020) (8)
In Vitro and In Vivo Models to Assess the Immune-Related Effects of Nanomaterials (2021) (8)
Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor. (1992) (8)
Personalised Profiling of Innate Immune Memory Induced by Nano-Imaging Particles in Human Monocytes (2021) (8)
Challenges in the design of clinically useful brain-targeted drug nanocarriers. (2014) (7)
Non-inflammatory peptide fragments of IL1 as safe new-generation adjuvants. (1992) (7)
Anti-inflammatory activity of IFN-beta in carrageenan-induced pleurisy in the mouse. (1986) (7)
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions * (7)
A Step-by-Step Approach to Improve Clinical Translation of Liposome-Based Nanomaterials, a Focus on Innate Immune and Inflammatory Responses (2021) (7)
SERS Sensing of Bacterial Endotoxin on Gold Nanoparticles (2021) (7)
Quantitation of biologically active IL-1 by a sensitive assay based on immobilized human IL-1 receptor type II (IL-1RII). (1991) (7)
Microplastics Interact with SARS-CoV-2 and Facilitate Host Cell Infection (2022) (7)
Peyer's patch lymphocytes express natural cytotoxicity but not natural killer activity. (1983) (7)
Interaction of engineered nanomaterials with the immune system: Health-related safety and possible benefits (2018) (6)
Asbestos-induced Modulation of Release of Regulatory Molecules from Alveolar and Peritoneal Macrophages (1986) (6)
Adjuvant activity of the 163-171 peptide of human IL-1 beta administered through different routes. (1987) (6)
Nano-immunosafety: issues in assay validation (2011) (6)
Human interleukin 1: structure-function relationship. (1990) (5)
Antibodies for Infectious Diseases (2015) (5)
A short synthetic peptide fragment of human interleukin-1 beta increases both human and murine natural killer activity. (1989) (5)
IL-1 receptor subtypes possess distinct binding properties for IL-1 alpha and IL-1 beta. (1990) (5)
Concern-Driven Integrated Toxicity Testing Strategies for Nanomaterials - Report of the NanoSafety Cluster Working Group 10 (2014) (5)
MACROPHAGE ACTIVATION FOR TUMOR CYTOTOXICITY: GENETIC INFLUENCES ON DEVELOPMENT OF MACROPHAGES WITH NONSPECIFIC TUMORICIDAL ACTIVITY (1980) (5)
Serum and urinary levels of IL-18 and its inhibitor IL-18 BP in systemic lupus erythematosus (2010) (5)
Cytokines in inflammation. Joint Workshop of the Deutsche Gesellschaft für Immunologie (DGfI) and the Gruppo di Cooperazione in Immunologia (GCI) Assergi (L'Aquila, Italy), February 8-11, 1998. (1998) (5)
Primary and Memory Response of Human Monocytes to Vaccines: Role of Nanoparticulate Antigens in Inducing Innate Memory (2021) (5)
Recombinant BCG Expressing the Subunit 1 of Pertussis Toxin Induces Innate Immune Memory and Confers Protection against Non-Related Pathogens (2022) (4)
Interaction between interleukin-1 and ciliary neurotrophic factor in the regulation of neuroblastoma cell functions. (1997) (4)
Stockport Emotion Map (2007) (4)
Neutrophil apoptosis in autoimmune Fas-defective MRL lpr/lpr mice. (2001) (4)
Regulation of macrophage functions by interferon. (1982) (4)
Methodological Approaches To Assess Innate Immunity and Innate Memory in Marine Invertebrates and Humans (2022) (4)
Changes underway in Italy. (1984) (4)
Chapter 10 – Immune System (2012) (4)
Chapter 1 – How Innate and Adaptive Immunity Work (2014) (4)
What Is IL-1 for? The Functions of Interleukin-1 Across Evolution (2022) (4)
Assessing Immunological Memory in the Solitary Ascidian Ciona robusta (2019) (4)
Modulation of Macrophage Activation (2016) (4)
Nanoparticles and Innate Immunity (2014) (3)
Antibacterial activity against Streptococcus pneumoniae by mouse lung lymphocytes. (1987) (3)
Effect of the age-related immune depression induced by MTV on the in vivo growth of a mammary carcinoma. (1981) (3)
Effects of whole-body irradiation on antibody affinity. (1977) (3)
Innate Memory Reprogramming by Gold Nanoparticles Depends on the Microbial Agents That Induce Memory (2021) (3)
Interleukin-1 beta induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti-tumor effects of tumor necrosis factor alpha or beta. (1989) (3)
Helicobacter pylori Infection of Primary Human Monocytes Boosts Subsequent Immune Responses to LPS (2022) (3)
Type II interleukin-1 receptor is not expressed in cultured endothelial cells and is not involved in endothelial cell activation. (1993) (3)
Chapter 13 – Immune System (2017) (3)
Immune Rebalancing : The Future of Immunosuppression (2016) (3)
Editorial: Interaction Between the Immune System and Nanomaterials: Safety and Medical Exploitation (2016) (3)
Differential inhibition of IL-1 beta activities and receptor binding by monoclonal antibodies mapping within a discrete region of the protein. (1991) (3)
Metabolic behavior and distribution of the synthetic nonapeptide fragment 163-171 of human IL-1 beta. (1990) (2)
INNAMORA, a European Workshop focussed on the mechanisms of innate immunity in pathogen–host interaction and their exploitation in novel mucosal immunisation strategies (2003) (2)
Sporulation: An alternative way to recover recombinant proteins from Bacillus subtilis (1995) (2)
Direct LC-MS/MS Analysis of Extra- and Intracellular Glycerophosphoinositol in Model Cancer Cell Lines (2021) (2)
Nanoparticles and the immune system (2012) (2)
Vaccines of the Future: The Role of Inflammation and Adjuvanticity (2015) (2)
Cellular immunity against Salmonella typhi after live oral vaccine. (1985) (2)
Association between Microorganisms and Microplastics: How Does It Change the Host–Pathogen Interaction and Subsequent Immune Response? (2023) (2)
Influence of the peptide insolubilization method on detection of anti-peptide antibodies in ELISA. Evaluation of nonspecific interactions. (1989) (2)
Nanoparticles and Immunological Frailty (2014) (2)
The SARS-CoV-2 Nucleoprotein Induces Innate Memory in Human Monocytes (2022) (2)
One hits (almost) all (2019) (2)
Erratum: IL-1 family nomenclature (2011) (2)
Natural antiviral activity of mouse macrophages against encephalomyocarditis virus. (1985) (2)
Poverty-Related Diseases College: a virtual African-European network to build research capacity (2016) (2)
Arachidonic acid metabolism in macrophages: Regulation by interferons and interleukin 1 (1985) (2)
Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis (2014) (1)
Studies on the Expression of Spontaneous Interferon-Like Activity in Mouse Peritoneal Cells (1987) (1)
Injections of Interleukins Around Tumor-Draining Lymph Nodes: A New Mode of Immunotherapy (1989) (1)
The 163-171 peptide of human IL-1 beta. (1990) (1)
INTERLEUKIN 1 AND ITS SYNTHETIC PEPTIDE 163-171 AS VACCINE ADJUVANTS (1997) (1)
Synthetic peptides of interleukin-1: Towards a dissociation of functions (1988) (1)
Monoclonal antibodies against a synthetic peptide of human il 1 beta as probes for membrane il 1 (1987) (1)
The Interleukin-1 System: Physiopathology and New Insights for its Therapeutical Potential (1992) (1)
Natural antibacterial activity against Salmonella typhi in human cord blood. (1989) (1)
The hidden toxin. Is bacterial lipopolysaccharide contamination responsible for nanomaterial toxicity (2017) (1)
Robust Immune Response Induced by Schistosoma mansoni TSP-2 Antigen Coupled to Bacterial Outer Membrane Vesicles (2021) (1)
Engineered Nanoparticles and the Immune System: Interaction and Consequences (2016) (1)
Modulation of Defense Cell Functions by Nano-Particles in Vitro (2003) (1)
Identification of a Novel Tumor-Derived Monocyte Chemotactic Factor: Relationship with Tissue Inhibitor of Metalloproteinase (1993) (1)
Interaction between nanomaterials and the innate immune system across evolution (2023) (1)
Radiolabeling of the biologically active peptide 163-171 of human interleukin-1 beta. (1990) (1)
Development of biologicals for the therapy of lupus erythematosus (2007) (1)
T cell independent induction of antigen specific suppression of the antibody response (1979) (0)
Synthesis and Biological Activity of the Immunomodulatory Site of Interleukin 1 (1987) (0)
Partial retro-inverted analogue of tuftsin, method for their preparation and pharmaceutical compositions containing them. (1987) (0)
Effects ofintraperitoneal recombinant interleukin-lB inintraperitoneal humanovarian cancerxenograft models: comparison withtheeffects of tumournecrosis factor (1992) (0)
Antarctized” antibody: an innovative engineered antibody by the CRISPR/Cas9 system Tutor: Dott.ssa (2020) (0)
2 . 3 Origin of Macrophages (0)
Effect of oral and intraperitoneal administration of BCG on cellular immune responses in the mouse small intestine (1980) (0)
Optimizing Response to Vaccination in the Elderly (2014) (0)
Model of ligand/receptor complex formation by the IL-1-like cytokines IL-18 and IL-1F7 with IL-18RRα and with the accessory protein IL-18RRβ. (2007) (0)
Macrophages (PP-047) (2010) (0)
Analogs inverso tuftsin partially, method of preparation thereof and pharmaceutical compositions containing them. (1987) (0)
Adjuvant activity of a synthetic nonapeptide of human interleukin 1β (1988) (0)
Effect of a synthetic nonapeptide of human IL-1b on the cellular immunoreactivity and in vivo growth of a fibrosarcoma of Balb/c mice (1988) (0)
MODULATION OF MACROPHAGE CYTOLYSIS BY INTERFERON (1982) (0)
An Evolutionary and Environmental Perspective of the Interaction of Nanomaterials with the Immune System (2022) (0)
Gold Nanoparticles Induce Cell Stress by Interfering with the Cellular Protein Quality Control System (2020) (0)
Meet Our Associate Editor (2016) (0)
Cytokine gene transfer in the therapy of autoimmune (2005) (0)
Editorial (Thematic Issue : Exploiting Knowledge on Nano-Immune Interactions: The Present and the Future) (2017) (0)
Induction of Innate Memory in Human Monocytes Exposed to Mixtures of Bacterial Agents and Nanoparticles (2022) (0)
DEFECTIVE TUMORICIDAL CAPACITY OF MACROPHAGES FROM P/J MICE: TUMORICIDAL DEFECT INVOLVES ABNORMALITIES IN MONONUCLEAR PHAGOCYTE RESPONSIVENESS LYMPHOKINE-DERIVED ACTIVATION STIMULI AND IN (1980) (0)
Synthetic interleukin 1 fragments with agonist activity (1990) (0)
and IL-6) and are activated and stimulated to grow by IL-1 granulocyte-monocyte-CSF, macrophage- CSF, interleukin-1 (IL-1), (granulocyte colony-stimulating factor (CSF), Human peritoneal mesothelial cells produce many cytokines (2012) (0)
Process for preparing synthetic peptides with human interleukin 1 activity. (1986) (0)
export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases Levels of plasma membrane expression in progressive and benign mutations of the bile salt (2007) (0)
Genetic analysis of the macrophage tumoricidal defect of a/j mice. Abstr. (1979) (0)
Pharmacological Strategies Using Biologics as Immunomodulatory Agents (2016) (0)
Synthetic peptide with human interleukin 1-effectiveness. (1986) (0)
Editorial: Exploring impacts of combined exposures to particles and chemicals on immune reactions across living organisms (2023) (0)
Interferon-induced macrophages cytolytic activity against tumor cells (1980) (0)
Impact of engineered nanoparticles in initiating or modulating pathology-related Inflammation (2016) (0)
Effects of andrographolide on the expression of IL-18 related cytokines in human PBMC/PBM. (2010) (0)
Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control (2023) (0)
The interleukin-1 family cytokines and receptors in autoimmune and autoinflammatory diseases (2009) (0)
Environment-Breast Cancer Link and Community Outreach Targeted (1994) (0)
Engineering of IL-1 Antagonists (1994) (0)
A short synthetic peptide fragment of human interleukin 1 β (hIL-1β) increases human natural killer (NK) activity (1987) (0)
IL-18 in autoimmunity. Studies in autoimmune murine lupus and in human SLE (2007) (0)
IgA-Armed T Lymphocytes as Anti-S. Typhi Effectors in Humans (1988) (0)
SERS-based nanotoxicology assessment of gold nanoparticles (2021) (0)
cells and is not involved in endothelial cell activation Type II interleukin-1 receptor is not expressed in cultured endothelial (2011) (0)
Invitro generated mastcells expressnatural cytotoxicity against tumourcells (1985) (0)
Postoperative delirium is associated with grey matter brain volume loss (2023) (0)
Nanoparticles and the immune system Evolution of innate immunity , lessons learned for assessing safety and efficacy of nanomaterials and nanodrugs (2018) (0)
Active fragments of IL-1: towards a dissociation of the functions? (1987) (0)
Gold Nanoparticles contaminated by Bacterial Endotoxin: biophysical characterization, imaging and nanotoxicology (2020) (0)
Regulatory activity of interferon on macrophage cytolytic and suppressive capacity (1982) (0)
Innate Immune Cells: Key Regulators of Homeostasis and Inflammation in Gut and Airway Mucosae (2014) (0)
Natural killer activity of murine large granular lymphocytes growing in interleukin-2 (1982) (0)
Modulation of alveolar and peritoneal macrophage activities by interferon and lymphokines (1985) (0)
Lymphocyte activating factor activity in the serum and cerebrospinal fluid of patients with multiple sclerosis (1990) (0)
Genetic aspects of macrophage activation for tumor cytotoxicity. (1982) (0)
Book Reviews (2006) (0)
Antibacterial activity of lymphocytes armed with IgA. (1987) (0)
NATURAL ANTIBACTERIAL ACTIVITY AGAINST CORD BLOOD SaZrnoneZZa typhi IN HUMAN (1989) (0)
Spike Protein Targeting “Nano-Glue” that Captures and Promotes SARS-CoV-2 Elimination (2021) (0)
100 Years of BCG Immunization: Past, Present, and Future (2022) (0)
Receptor Accounts for Inhibitory Function The Membrane Form of the Type II IL-1 (2000) (0)
Interaction of nanoparticles with the immune system (2015) (0)
Type I 1 Interleukin-1 Receptor Is Not Expressed in Cultured Endothelial Cells and Is Not Involved in Endothelial Cell Activation (2003) (0)
Local and systemic immunity after typhoid vaccines. (1986) (0)
Symposium: The role of macrophages in tumor immunology. (1979) (0)
THU0063 IL-1 family cytokines and receptors in IGG4-related disease (2017) (0)
Macrophage activation for tumor cytotoxicity depends upon genetic factors. Abstr. (1979) (0)
Editorial: Immunological Effects of Nano-Imaging Materials (2022) (0)
MAP OF THE EXPRESSION (2017) (0)
Serum Interleukin Profile in Normal Subjects and in Patients with or at Risk of Alzheimer's Disease (2018) (0)
2015 Reviewer Acknowledgments (2016) (0)
Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression? (2018) (0)
Defective tumoricidal capacity of macrophages from a-derived strains of mice. Abstr. (1978) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Diana Boraschi?

Diana Boraschi is affiliated with the following schools: